A long-term follow-up of botulinum toxin A in cervical dystonia

Mohammadi, Bahram; Buhr, Nicole de; Bigalke, Hans; Kenn, Klaus; Dengler, Reinhard; Kollewe, K.

doi:10.1179/174313209x405137

Cited by 69 publications

(52 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evidence of maintained response in this study is consistent with a previous long-term observational study, whereby the extended efficacy of Dysport (mean dose: 389 ± 144 U) was demonstrated in 163 (of a total population of 207) patients with CD who had received treatment for up to 14 years [11]. Maintenance of efficacy with Dysport is further supported by a long-term study of 108 patients with CD [10].…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

A 17-year Experience of AbobotulinumtoxinA in Cervical Dystonia

Vivancos-Matellano

Ybot-Gorrin

Tejedor

2012

International Journal of Neuroscience

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 87%

“…Dysphagia was the most common AE, was mild in all reported cases, and did not lead to treatment discontinuation. The favorable tolerability profile of Dysport in this study is in agreement with both short-and long-term controlled and observational studies in patients with CD [7,8,10,11].…”

Section: Long-term Bont-a For Cervical Dystonia 357supporting

confidence: 89%

A 17-year Experience of AbobotulinumtoxinA in Cervical Dystonia

Vivancos-Matellano

Ybot-Gorrin

Tejedor

2012

International Journal of Neuroscience

View full text Add to dashboard Cite

show abstract

“…While other long-term studies have been reported, these were generally conducted retrospectively26 27 or did not assess clinical efficacy outcomes at the peak effect of treatment 7…”

Section: Discussionmentioning

confidence: 99%

Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia

Dressler

Seitzinger

Gebhardt

et al. 2013

Journal of Neurology, Neurosurgery & Psychiatry

Self Cite

View full text Add to dashboard Cite

IntroductionPreviously, controlled trials have demonstrated the efficacy and tolerability of fixed doses of incobotulinumtoxinA (Xeomin, NT 201, botulinum toxin type A free from complexing proteins) to treat cervical dystonia (CD). To explore the clinical relevance of these findings, this study evaluated long-term use of flexible dosing regimens of incobotulinumtoxinA in a setting close to real-life clinical practice.MethodsPatients with CD received five injection sessions of incobotulinumtoxinA using flexible intervals (10–24 weeks) and dosing (≤300 Units) based on patients’ needs. Outcome measures included Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), the Dystonia Discomfort Scale (DDS), Investigator Global Assessment of Efficacy (IGAE) and Patient Evaluation of Global Response (PEGR).ResultsOf 76 patients enrolled (men: 34%; naïve to botulinum toxin: 25%), 64 completed the study, receiving treatment over a duration of 49.3–114.1 weeks (total maximum duration: 121 weeks). Mean TWSTRS-Total and DDS scores significantly improved from study baseline to 4 weeks after each injection session (ranges of improvement: TWSTRS-Total: −11.7 to −14.3; DDS: −20.2 to −23.0). Up to 81.6% of investigators rated the efficacy as ‘good’ or ‘very good’ (IGAE) and up to 78.9% of patients rated the treatment response as ‘improved’ (PEGR). The most common adverse events were dysphagia, nasopharyngitis and headache.ConclusionsIn this long-term study, incobotulinumtoxinA was administered using more flexible dosing regimens than those permitted in previous controlled trials. Repeated injections of highly purified incobotulinumtoxinA are effective and well tolerated for the treatment of CD in a setting close to real-life clinical practice.

show abstract

“…Response rates of approximately 80% have been achieved in patients with CD in open and double-blind studies [9][10][11] . Furthermore, treatment is generally well tolerated even following long-term administration 12,13 and the risk of adverse events may also be minimized using well-defined injection procedures.…”

Section: Introductionmentioning

confidence: 99%